Acting Interim Chair
Office: IDRB 214
Lab: IDRB 214
B.A., University of South Florida
Ph.D., University of South Florida
Postdoctoral Associate, Duke University
Sr. Postdoctoral Associate, Columbia University
Dr. Wayne C. Guida is Professor in the Department of Chemistry, University of South Florida in Tampa and Professor in the Drug Discovery Program at the H. Lee Moffitt Cancer Center & Research Institute at the University of South Florida.
He is the author or co-author of over 80 research publications, holds 9 patents, and has been PI/Co-PI on over 10 research contracts/grants.
Research from the Guida lab has been cited more than 8,000 times.
Prior to coming to USF/Moffitt, Dr. Guida served as President and CEO of Schrödinger, Inc. and continues to serve on the company’s Scientific Advisory Board.
Prior to his role as CEO of Schrödinger, he was Executive Director of Biomolecular Structure, Lead Finding, and Computing at the Novartis Institute for Biomedical Research (formerly CIBA-Geigy Pharmaceuticals) in Summit, New Jersey, where he supervised a group of scientists engaged in molecular modeling, structural bioinformatics, X-ray crystallography, protein NMR spectroscopy, protein biochemistry, and high-throughput screening.
His work at CIBA-Geigy, along with collaborators at the University of Alabama at Birmingham, Southern Research Institute and BioCryst Pharmaceuticals, resulted in one of the first successful examples of the use of Structure-Based Drug Design in drug discovery.
That work led to the development of clinically tested inhibitors of purine nucleoside phosphorylase.
Prior to joining CIBA-Geigy, Dr. Guida was one of the original developers of the MacroModel program at Columbia University.
Dr. Guida’s main research interests include the design of inhibitors of enzymes in signal transduction pathways and the biosynthetic pathways of polyamines and lipids.
These inhibitors have potential utility as drugs for the treatment of cancer and infectious diseases.
The discovery, design and synthesis of non-covalent, copper-based 20S proteasome inhibitors for the treatment of cancer is also an area of significant interest to Dr. Guida’s group.
View our currently funded projects here.
left to right:
Grace Binder (research assistant), Sreya Mukherjee (grad student), Dr. Wesley Brooks (Research Assistant Professor ),
Dr. Wayne Guida, Dr. Kenyon Daniel (Staff Scientist, Moffitt Cancer Center and Asst. Professor, CMMB),
Rainer Metcalf (grad student). Not shown: Robert Sparks (research assistant), Tyler Waid (undergraduate),
Mariafernanda Davila (undergraduate).
Rainer Metcalf, Sreya Mukherjee
“Orally bioavailable 6-chloro-7-methoxy-4(1H)-quinolones efficacious against multiple stages of Plasmodium.“
Cross RM, Flanigan DL, Monastyrskyi A, LaCrue AN, Sáenz FE, Maignan JR, Mutka TS, White KL, Shackleford DM, Bathurst I, Fronczek FR, Wojtas L, Guida WC, Charman SA, Burrows JN, Kyle DE, Manetsch R.
J Med Chem., 2014, 57, 8860.
“In silico characterization of an atypical MAPK phosphatase of Plasmodium falciparum as a suitable target for drug discovery.“
Campbell CO, Santiago DN, Guida WC, Manetsch R, Adams JH.
Chem Biol Drug Des., 2014, 84, 158.
“Production of recombinant 1-deoxy-d-xylulose-5-phosphate synthase from Plasmodium vivax in Escherichia coli.“
Handa S, Ramamoorthy D, Spradling TJ, Guida WC, Adams JH, Bendinskas KG, Merkler DJ. FEBS
Open Bio., 2013, 3, 124.
“Development of new N-Arylbenzamides as STAT3 Dimerization Inhibitors.“
Urlam MK, Pireddu R, Ge Y, Zhang X, Sun Y, Lawrence HR, Guida WC, Sebti SM, Lawrence NJ.
Medchemcomm., 2013, 4, 932.
“Identification of a New Binding Site in E. coli FabH using Molecular Dynamics Simulations: Validation by Computational Alanine Mutagenesis and Docking Studies.“
Ramamoorthy D, Turos E, Guida WC.
J Chem Inf Model., 2013, 53,1138.
“Oxadiazole-isopropylamides as Potent and Noncovalent Proteasome Inhibitors.“
Ozcan S, Kazi A, Marsilio F, Fang B, Guida WC, Koomen J, Lawrence HR, Sebti SM.
J Med Chem., 2013, 56, 3783-3805.
“A novel inhibitor of STAT3 homodimerization selectively suppresses STAT3 activity and malignant transformation.“
Zhang X, Sun Y, Pireddu R, Yang H, Urlam MK, Lawrence HR, Guida WC, Lawrence NJ, Sebti SM.
Cancer Res., 2013,73,1922.
“Virtual target screening: validation using kinase inhibitors.“
Santiago DN, Pevzner Y, Durand AA, Tran M, Scheerer RR, Daniel K, Sung SS, Lee Woodcock H, Guida WC, Brooks WH.
J Chem Inf Model. 2012, 52, 2192.
“Fragment-Based and Structure-Guided Discovery and Optimization of Rho Kinase Inhibitors“
Li R, Martin MP, Liu Y, Wang B, Patel RA, Zhu JY, Sun N, Pireddu R, Lawrence NJ, Li J, Haura EB, Sung SS, Guida WC, Schonbrunn E, Sebti SM.
J Med Chem. 2012, 55, 2474.
“Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2).“
Pireddu R, Forinash KD, Sun NN, Martin MP, Sung SS, Alexander B, Zhu JY, Guida WC, Schönbrunn E, Sebti SM, Lawrence NJ.
Medchemcomm., 2012, 3, 699.
“Discovery and Synthesis of Hydronaphthoquinonesas Novel Proteasome Inhibitors“
Ge Y, Kazi A, Marsilio F, Luo Y, Jain S, Brooks W, Daniel KG, Guida WC, Sebti SM, Lawrence HR.
J Med Chem. 2012, 55, 1978.
“Synthesis and evaluation of substituted hexahydronaphthalenes as novel inhibitors of the Mcl-1/BimBH3 interaction.“
Kim YB, Balasis ME, Doi K, Berndt N, DuBoulay C, Hu CC, Guida W, Wang HG, Sebti SM, Del Valle JR.
Bioorg Med Chem Lett., 2012 22, 5961.